Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to $217.3 million.

  • Vanda Pharmaceuticals' Non-Current Assets rose 9.83% to $233.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.6 million, marking a year-over-year increase of 9.83%. This contributed to the annual value of $217.3 million for FY2024, which is 0.84% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Non-Current Assets stood at $217.3 million for FY2024, which was up 0.84% from $215.5 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Non-Current Assets registered a high of $217.3 million during FY2024, and its lowest value of $115.0 million during FY2022.
  • In the last 3 years, Vanda Pharmaceuticals' Non-Current Assets had a median value of $215.5 million in 2023 and averaged $182.6 million.
  • In the last 5 years, Vanda Pharmaceuticals' Non-Current Assets fell by 7.10% in 2021 and then soared by 87.46% in 2023.
  • Vanda Pharmaceuticals' Non-Current Assets (Yearly) stood at $124.3 million in 2020, then fell by 7.10% to $115.5 million in 2021, then declined by 0.46% to $115.0 million in 2022, then spiked by 87.46% to $215.5 million in 2023, then rose by 0.84% to $217.3 million in 2024.